Latest News

DAIICHI SANKYO, INC: Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within its AML Franchise in Patients with AML

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in the first novel-novel combination study evaluating two investigational agents within its AML Franchise.

ABCO SYSTEMS: Conveyor System Maintenance

ABCO Systems offers conveyor maintenance and here is why.

MERCK: European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection.

BD: BD Announces Completion Of Enterprise Level Cybersecurity Assessment From UL

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL.

CELGENE CORPORATION: Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

KONICA MINOLTA BUSINESS SOLUTIONS U.S.A. INC: Konica Minolta Strengthens Workplace Of The Future Offering With The Launch Of The Acuant i-Dentify 150 Scanner To Confirm Visitor Identity

Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) today announced selection of the Acuant i-Dentify™ 150 Scanner, with Wintech’s ID Scan & Validate Subscription Plug-In, to complement the ALICE® Receptionist visitor management system.

BD: BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversion

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new software application designed to help hospitals and health systems identify drug diversion at the 2018 American Society of Health-System Pharmacists (ASHP) Midyear Meeting

CELGENE CORPORATION: Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma

Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies’ lead investigational anti-BCMA CAR T cell therapy candidate for patients with relapsed and refractory multiple myeloma.

CORPORATE ESSENTIALS: Rickaroons: The New Standard For Delicious Energy Snacks

The search for a healthy and delicious, dietary friendly energy snack is over!

MERCK: Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has started the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated), the company’s investigational vaccine for Ebola Zaire disease.

MERCK: FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for priority review for the approval of LYNPARZA tablets as a maintenance treatment in patients with newly-diagnosed, BRCA-mutated (BRCAm) advanced ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy.

KONICA MINOLTA BUSINESS SOLUTIONS U.S.A, INC: Konica Minolta’s AccurioJet KM-1 UV Inkjet Press Offers New Opportunities to Expand Small Business Client Base

Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) is pleased to announce that our Accuriojet KM-1 UV Inkjet press continues to transform small and medium-sized businesses (SMBs) by expanding their opportunities to break into new markets, offer new products, and increase profits.

MERCK: FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

CELGENE CORPORATION: Celgene Named Among World’s Best Employers 2018

Celgene has long maintained a dual focus on not only the patients that its therapies treat but the employees at Celgene that work to develop those therapies and get them to market.

CELGENE CORPORATION: Light The Night Helps Lead the Way for Blood Cancer Research

Although survival rates for blood cancer have improved over the past decade, it remains the third deadliest type of cancer in the U.S.

GOTHAM TECHNOLOGY GROUP: NIST to Develop Privacy Framework

The U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) announced on September 4, 2018 that it has started a collaborative project to develop a voluntary privacy framework.

NEW JERSEY CHAMBER OF COMMERCE: Statement from N.J. Chamber of Commerce President Tom Bracken on Gov. Murphy's Economic Development Plan

We applaud Gov. Murphy for putting forth a strong vision for New Jersey’s economic future and an inspiring view of what New Jersey can be.

Metro Business Network